Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer

Summary

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic body radiation therapy together with gemcitabine hydrochloride may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of stereotactic body radiation therapy when given with or without gemcitabine hydrochloride in treating patients with pancreatic cancer that can be removed by surgery.

Timeline

Start

2009-10

Primary completion

2011-02-18

Completion

2011-02-18

Outcome

Outcome not reported

Stopped: “DSMC closed due to patient deaths”

Drugs

Indications